### **Overview** Supriya Lifescience Ltd., founded in 1987 and headquartered in Mumbai, is a global manufacturer of active pharmaceutical ingredients (APIs) and intermediates, serving both innovator and generic pharmaceutical companies. The company operates as a dedicated contract manufacturing organization (CMO/CDMO) for select global partners and is recognized for its expertise in complex chemistries, backward integration, and regulatory compliance across key international markets. With a strong presence in over **120 countries** and revenue from exports constituting **~86%** of total income, Supriya Lifescience has established itself as a trusted supplier in regulated markets such as the US, EU, Japan, Canada, and Latin America. The company's manufacturing facilities are approved by **USFDA, EUGMP, EDQM, Health Canada, PMDA, ANVISA, WHO, and others**, affirming its adherence to the highest global quality standards. --- ### **Strategic Positioning & Competitive Advantage** #### **1. Backward Integration & Supply Chain Resilience** - The company has **backward-integrated 18 products** across anesthetics, anti-asthmatics, anti-histamines, decongestants, and anti-gout medications, with plans to integrate **3 more**. - Achieved **72% backward integration** by FY2024, reducing reliance on Chinese suppliers and enhancing margin sustainability. - In-house synthesis from basic raw materials enables **end-to-end control**, superior impurity profiling, and reduced regulatory risk. #### **2. Regulated Market Focus** - Exports account for **85–86% of revenue**, with over **half of sales** in high-margin regulated markets (EU, US, Japan, Australia). - Strong traction in **Latin America**, which contributed **21% of Q1 FY25 revenue**, with full-market potential estimated at **INR 200 crores**. - North America’s contribution expected to grow from low-single digits to **~10% over the next 3–4 years**. - Over **70% of revenue** comes from **customers with 5+ years of relationship**, indicating strong retention and trust. #### **3. Robust R&D Infrastructure & Innovation** - A **team of 60+ scientists** drives API process development across the value chain. - Operates **two dedicated R&D centers**: - **Ambernath (Maharashtra)**: Focused on formulations, new product development, and CMO/CDMO opportunities. - **Lote Parshuram (Maharashtra)**: 800 sqm facility with **20 fume hoods**, dedicated to generic APIs, lifecycle management, and backward integration. - Filed **4 process patents in India**, including a low-cost, high-efficiency method for **Atorvastatin** and synthesis routes for **Enzalutamide** and **Esketamine HCl**. - Active regulatory portfolio includes **14 USDMFs**, **8–10 CEPs**, and **multiple CADIFA filings** in Brazil. #### **4. Expansion into Diverse Therapeutic Areas** - Core therapeutic strengths: **Anti-histamines, anti-allergics, anesthetics, vitamins, anti-asthmatics**. - **Strategic expansion areas**: - **Contrast Media, Cardiovascular, ADHD, Anti-Diabetics, Anti-Anxiety, Anti-Gout, CNS, and Controlled Drugs**. - Launched a novel **anesthetic product (Q4 FY24)** and planning to launch **3–4 new products annually**, with 2 already launched in FY25: an anesthetic and a cardiovascular advanced intermediate. --- ### **Manufacturing & Capacity Expansion** #### **Lote Parshuram Facility (Ratnagiri, Maharashtra)** - **Total reactor capacity: 932 KLPD** (increased from 597 KLPD via **55% expansion**). - **Module E (E Block) commissioned in Dec 2024** at a cost of **₹125 crore**, adding **335 KLPD** of multipurpose synthesis capacity. - Facility spans **33,000 sq. meters** across **5 therapy-specific manufacturing blocks**. - Certified by **USFDA, EUGMP, ANVISA, PMDA, KFDA, Health Canada, and others**. #### **Ambernath Facility (Maharashtra)** - Under development: **New formulation plant and dedicated R&D center**. - Will support **finished dosage forms**, including **solid, liquid, injectables, and nasal sprays**. - Enables forward integration and value addition through **API-to-formulation solutions**. - Expected to drive **CDMO/CMO growth**, especially for **value-added injectables and oral solids**. #### **Future Expansion** - Acquired **three additional land parcels** near Lote and Ambernath for future capacity and backward integration. - Planning to **double total reactor capacity to ~1,020 KLPD**. --- ### **Growth Drivers & Business Model** #### **1. CMO/CDMO Growth Strategy** - **DSM Vitamin Project**: Commercialized, with **₹25–30 crore revenue in FY25**, peak potential of **₹60–70 crore**. - USDMF, CEP, and PMDA approvals secured; pharmaceutical supply awaits final customer qualification. - Secured **exclusive 10-year CMO contract** with a European firm, generating **₹60 crore** peak annual revenue from FY27. - Pipeline includes **2–3 advanced API/intermediate CMO projects**. - CMO/CDMO segment expected to contribute **20% of total revenue (~₹200 crores) by FY26–27**. #### **2. Product Diversification & Innovation** - **New Product Pipeline**: - **ADHD product (launch Q3 FY25)**. - **Contrast Media product (launch Q3–Q4 FY25)**. - **Peptide APIs** under development: **Semaglutide**, with commercial launch expected in ~2.5 years. - Expanding into **non-therapeutic consumer health** with: - **Whey protein formulation (ioWHEY)** in partnership with **US-based Plasma Nutrition**. - **Alternative proteins** (pea, collagen) targeted for global markets (China, Singapore, Malaysia). - Developing **patent-pending technologies** like: - **QuickBlue**: Low-cost, rapid **oral cancer detection kit** (in partnership with KIIT). - **GelHeal**: Protein-based **wound healing hydrogel** for burns and ulcers. #### **3. Financial & Capital Allocation Strategy** - **Revenue Target**: **₹1,000 crores by FY26–27** (up from ~₹575 crores in FY24–25). - **EBITDA Margins**: Target **33–35%**, with strong visibility due to regulated market sales. - **Net Debt/Equity**: **0.01x**, indicating robust financial stability. - **CAPEX (FY24–25)**: Increased fixed assets from ₹360 to ₹523 crore, driven by E Block and solar infrastructure. - **R&D CAPEX**: ₹6.37 crore in FY24–25, with continued focus on innovation and automation. --- ### **Regulatory & Geographic Strengths** - **Global Regulatory Approvals**: - **USFDA**: Multiple inspections passed. - **EDQM/CEP**: 8–10 active CEPs. - **ANVISA (Brazil)**: First Indian company approved for **Esketamine HCl**. - Expanding in **Australia, Japan, New Zealand**. - **Market Diversification**: - **Europe**: ~41% of revenue. - **Asia (excl. India)**: ~38%. - **Latin America**: ~21% (high-growth region). - Reduced exposure to China—**China revenue down to <2%**, with focus on **non-China markets** accounting for **99% of revenue in FY24–25**. --- ### **Strategic Vision** Supriya Lifescience aims to **evolve into a fully integrated pharmaceutical enterprise**, covering the entire value chain from **API development to finished dosage forms**. The company is leveraging the **‘China+1’ strategy**, offering **Indian-origin, GMP-certified, alternative supply solutions** for global pharma firms. Its growth is driven by: - **Backward integration** for cost and supply control. - **Innovation-led R&D** and **patent-protected processes**. - **CDMO/CMO expansion** in regulated markets. - **Entry into niche, high-growth therapeutic areas** with limited competition. --- ### **Key Milestones (Recent & Upcoming)** | **Milestone** | **Status / Timeline** | |---------------|------------------------| | Module E Commissioned (335 KLPD) | **Dec 2024 / Nov 2025 operational** | | Ambernath Formulation Plant | Under development, partial ops expected by **H2 FY25** | | New Product Launches (Anesthetic, Cardio, ADHD, Contrast Media) | **2 launched, 2 in final stages (FY25)** | | DSM Vitamin Project Commercialization | **Ongoing (food/feed), pharma supply in 4–5 months** | | 10-Year European CMO Deal | Revenue from **FY27** | | CDMO Revenue Target | **₹100–200 crores in 2–3 years** | | Semaglutide (Peptide API) Launch | **Expected in ~2.5 years** | | Oral Cancer Detection Kit (QuickBlue) | **R&D phase, clinical trials upcoming** | ---